TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02820155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN1016
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN1016
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN1016
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN1016
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN1016
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
Study: NCT01850485

Intervention type: DEVICE
Intervention: microcirculation by SDF and NIRS, in 33 and 36 degrees
Description: at baseline, after 12 and 24 hours in both arms

Intervention type: DEVICE
Intervention: microcirculation by SDF and NIRS, in 33 and 36 degrees
Description: at baseline, after 12 and 24 hours in both arms
Study: NCT00077363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study: NCT02240979

Intervention type: DEVICE
Intervention: cardiac MRI
Description: cardiac MRI
Study: NCT03280875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pedalling exercises
Description: pedalling exercises on a bicycle ergometer
Study: NCT01301950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Custom Patient Instrumentation
Description: TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instruments
Description: Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
Study: NCT04144374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omadacycline
Description: Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis Catheter Insertion
Description: A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Catheter Insertion
Description: A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
Study: NCT03536975

Intervention type: OTHER
Group type: OTHER
Intervention: Platform
Description: The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it
Study: NCT04001075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ107
Description: Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
Study: NCT02491957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LOFT Therapy
Description: LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement.
Study: NCT04077450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Heart-Focused Breathing Intervention
Description: Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
Study: NCT06476522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Program
Description: In the first evaluation, 5 different exercises were shown and the patients were asked to do home exercises in accordance with the given program. The physiotherapist suggested starting with a 10-minute walk 5 times a week and then gradually increasing the walking time. The patients were given a program for balance and sensory training. They were asked to apply the physiotherapy program at least 3 days a week for 12 weeks. Weekly follow-up of the patients was carried out by the physiotherapist over the phone or face to face when they underwent routine treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: To Inform
Description: The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To Inform
Description: The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.
Study: NCT03786562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Morphine
Description: Group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine + Intravenous Nalbuphine
Description: Group 2
Study: NCT04502004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App for health=mhealth
Description: Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
Study: NCT02048618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: 100 mg oral tablet, intake once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo oral tablets, intake once daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral tablets, intake once daily for 20 weeks
Study: NCT04377711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 160mcg Inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Inhaler
Study: NCT01918423

Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention during pregnancy
Description: Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
Study: NCT02607683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5 (concentration A: 0.1%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5 (concentration B: 0.035%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study: NCT00555477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg tablet by mouth once a day
Study: NCT04275505

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shortwave diathermy treatment
Description: shortwave diathermy is a deep heating physical therapy agent. It was found efficiaous in carpal tunnel syndrome which is an entrapment neuropathy like ulnar nerve entrapment so it was hypothesised that shortwave diathermy could be an effective treatment method in ulnar nerve entrapment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo shortwave diathermy treatment
Description: shortwave device was not turned on while participants were asked to put their elbow into the device
Study: NCT01146704

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass
Description: Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate
Description: High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
Study: NCT03857204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAMPL plain wave algorithm
Description: SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
Study: NCT02680132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg DR Capsules of AstraZeneca LP, USA
Description: oral, cross over

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
Description: oral, cross over
Study: NCT03574753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-399
Description: ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
Study: NCT01274663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
Study: NCT04234165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: different power sources ( bipolar vs monopolar)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TURBT
Description: different power sources ( bipolar vs monopolar)
Study: NCT03853720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
Description: Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed.
Study: NCT04491539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finding Respect and Ending Stigma around HIV (FRESH)
Description: The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finding Respect and Ending Stigma around HIV (FRESH)
Description: The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
Study: NCT04538872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StraDiMS implicit
Description: participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StraDiMS implicit
Description: participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StraDiMs explicit
Description: participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StraDiMs explicit
Description: participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
Study: NCT00932360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS
Study: NCT01851642

Intervention type: PROCEDURE
Intervention: History and physical exam.
Description: At every study visit, participant's will be asked about their medical history and will have a physical exam.

Intervention type: PROCEDURE
Intervention: History and physical exam.
Description: At every study visit, participant's will be asked about their medical history and will have a physical exam.
Study: NCT00932360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Active TENS, Placebo TENS and No Treatment TENS
Study: NCT04687332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
Description: One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
Description: One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
Study: NCT02510092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with new generation fully resorbable scaffold
Study: NCT01651858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nurigra Chewable tablet
Description: 1 tablet of 100mg, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurigra Chewable tablet
Description: 1 tablet of 100mg, once a day
Study: NCT03777540

Intervention type: PROCEDURE
Intervention: Gastric resection
Description: Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery).
Study: NCT00924105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT013-IL1bQb
Description: s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c. injection
Study: NCT04060082

Intervention type: OTHER
Intervention: Telephone Interview
Description: Participants will be asked to answer questions about their experiences with FTD.

Intervention type: OTHER
Intervention: Telephone Interview
Description: Participants will be asked to answer questions about their experiences with FTD.
Study: NCT03256955

Intervention type: DEVICE
Group type: OTHER
Intervention: Tof cuff
Description: The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tof Watch SX
Description: The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
Study: NCT03041350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone video-assisted ALS(advanced life support)
Description: As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated